Pan Xuan, Li Chenchen, Feng Jifeng
Department of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, People's Republic of China.
Cancer Cell Int. 2023 Feb 21;23(1):30. doi: 10.1186/s12935-023-02872-3.
Cancer immunotherapy is a major breakthrough in the history of tumor therapy in the last decade. Immune checkpoint inhibitors blocking CTLA-4/B7 or PD-1/PD-L1 pathways have greatly prolonged the survival of patients with different cancers. Long non-coding RNAs (lncRNAs) are abnormally expressed in tumors and play an important role in tumor immunotherapy through immune regulation and immunotherapy resistance. In this review, we summarized the mechanisms of lncRNAs in regulating gene expression and well-studied immune checkpoint pathways. The crucial regulatory function of immune-related lncRNAs in cancer immunotherapy was also described. Further understanding of the underlying mechanisms of these lncRNAs is of great importance to the development of taking lncRNAs as novel biomarkers and therapeutic targets for immunotherapy.
癌症免疫疗法是过去十年肿瘤治疗史上的一项重大突破。阻断CTLA-4/B7或PD-1/PD-L1通路的免疫检查点抑制剂极大地延长了不同癌症患者的生存期。长链非编码RNA(lncRNAs)在肿瘤中异常表达,并通过免疫调节和免疫治疗抗性在肿瘤免疫治疗中发挥重要作用。在本综述中,我们总结了lncRNAs在调节基因表达和深入研究的免疫检查点通路中的机制。还描述了免疫相关lncRNAs在癌症免疫治疗中的关键调节功能。进一步了解这些lncRNAs的潜在机制对于将lncRNAs作为免疫治疗的新型生物标志物和治疗靶点的开发至关重要。